VELAPRUMIG
UNII 36J438MZ7Z
Substance Identification & Data
This profile provides standardized clinical and technical data for Velaprumig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 36J438MZ7Z.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2988741-17-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
36J438MZ7Z
2988741-17-7
N/A
Detailed Substance Profile
Preferred Name
VELAPRUMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13342
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
OP-133
Identifier assigned by the United States Adopted Names Council.
Substance Type
Velaprumig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Velaprumig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Velaprumig
Common Names & Synonyms
483) [scFvkh anti-CD40LG (1-245) [V-KAPPA Musmus/Homsap (Mus musculus IGKV3-7*01 (87.9%) -IGKJ1*02 (100%)/Homo sapiens IGKV3-11*01 (75.5%) -IGKJ4*01 (90.9%) V124>L (108), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1-112) -15-mer tris(tetraglycyl-seryl) linker (113-127) -VH Musmus/Homsap (Mus musculus IGHV1-47-14*01 (88.8%) -(IGHD) -IGHJ3*01 (90.9%) A128>S (245)/Homo sapiens IGHV1-46*01 (76.5%) -IGHD -IGHJ1*01 (100%), CDR-IMGT [8.8.11] (153-160.178-185.224-234)) (128-245)] -15-mer tris(tetraglycyl-seryl) linker (246-260) -VH-G1(CH1-h) anti-ALB (261-483) [VH anti-ALB (Homo sapiens IGHV3-21*01 (90.8%) -IGHD -IGHJ4*01 (92.9%), CDR-IMGT [8.8.13] (286-293.311-318.357-369)) (261-380) -Homo sapiens IGHG1*01 CH1-h, G1m17,1CH1 K120, 10-G1v100-1 CH1 E16, 15-G1v37 h S5 (CH1 G16>E (400), K120 (477) (381-478), hinge 1-5 C5>S (483) (479-483)) (381-483)]]; fused scFvkh-L-KAPPA chain anti-CD40LG and anti-ALB (1'-478') [scFvkh anti-CD40LG (1'-245') [V-KAPPA Musmus/Homsap (Mus musculus IGKV3-7*01 (87.9%) -IGKJ1*02 (100%)/Homo sapiens IGKV3-11*01 (75.5%) -IGKJ4*01 (90.9%) V124>L (108'), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-112') -15-mer tris(tetraglycylseryl) linker (113'-127') -VH Musmus/Homsap (Mus musculus IGHV1-47-14*01 (88.8%) -(IGHD) -IGHJ3*01 (90.9%) A128>S (245')/Homo sapiens IGHV1-46*01 (76.5%) -IGHD -IGHJ1*01 (100%), CDR-IMGT [8.8.11] (153'-160'.178'-185'.224'-234')) (128'-245')]-18-mer (GSTSGSGKPGSGEGSTKG) linker (246'-263') -L-KAPPA anti-ALB (264'-478') [V-KAPPA anti-ALB (Homo sapiens IGKV3-15*01 (85.7%) -IGKJ2*01 (90.9%) K123>Q (367'), CDR-IMGT [6.3.10] (290'-295'.313'-315'.352'-361')) (264'-371') -Homo sapiens IGKC*01, Km3 A45.1, V101, 15-KCv36 S126 (C-KAPPA A45.1 (417'), V101 (455'), C226>S (478') (372'-478')]], produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, non-glycosylated
Immunoglobulin G1, anti-(human CD40 ligand) (human-Mus musculus monoclonal hu5C8 single-chain variable fragment VL-(GGGGS)3-VH) fusion protein with peptide linker ((GGGGS)3) fusion protein with immunoglobulin G1, Fab fragment [140-glutamic acid, 223-serine], anti-(human serum albumin) (human monoclonal SL335 γ1-chain), complex with immunoglobulin, anti-(human CD40 ligand) (human-Mus musculus monoclonal hu5C8 single-chain variable fragment VL-(GGGGS)3-VH) fusion protein with peptide linker (GSTSGSGKPGSGEGSTKG) fusion protein with immunoglobulin [215-serine], anti-(human serum albumin) (human monoclonal SL335 κ-chain)
Immunoglobulin scFvkh-L-VH-G1(CH1-h)_scFvkh-L-kappa, anti-[Homo sapiens CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], monoclonal antibody, bispecific, trivalent; fused scFvkh-L-VH-G1(CH1-h) chain anti-CD40LG and anti-ALB (1-483) [scFvkh anti-CD40LG (1-245) [V-KAPPA Musmus/Homsap (Mus musculus IGKV3-7*01 (87.9%) -IGKJ1*02 (100%)/Homo sapiens IGKV3-11*01 (75.5%) -IGKJ4*01 (90.9%) V124>L (108), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1-112) -15-mer tris(tetraglycyl-seryl) linker (113-127) -VH Musmus/Homsap (Mus musculus IGHV1-47-14*01 (88.8%) -(IGHD) -IGHJ3*01 (90.9%) A128>S (245)/Homo sapiens IGHV1-46*01 (76.5%) -IGHD -IGHJ1*01 (100%), CDR-IMGT [8.8.11] (153-160.178-185.224-234)) (128-245)] -15-mer tris(tetraglycyl-seryl) linker (246-260) -VH-G1(CH1-h) anti-ALB (261-483) [VH anti-ALB (Homo sapiens IGHV3-21*01 (90.8%) -IGHD -IGHJ4*01 (92.9%), CDR-IMGT [8.8.13] (286-293.311-318.357-369)) (261-380) -Homo sapiens IGHG1*01 CH1-h, G1m17,1CH1 K120, 10-G1v100-1 CH1 E16, 15-G1v37 h S5 (CH1 G16>E (400), K120 (477) (381-478), hinge 1-5 C5>S (483) (479-483)) (381-483)]]; fused scFvkh-L-KAPPA chain anti-CD40LG and anti-ALB (1'-478') [scFvkh anti-CD40LG (1'-245') [V-KAPPA Musmus/Homsap (Mus musculus IGKV3-7*01 (87.9%) -IGKJ1*02 (100%)/Homo sapiens IGKV3-11*01 (75.5%) -IGKJ4*01 (90.9%) V124>L (108'), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-112') -15-mer tris(tetraglycylseryl) linker (113'-127') -VH Musmus/Homsap (Mus musculus IGHV1-47-14*01 (88.8%) -(IGHD) -IGHJ3*01 (90.9%) A128>S (245')/Homo sapiens IGHV1-46*01 (76.5%) -IGHD -IGHJ1*01 (100%), CDR-IMGT [8.8.11] (153'-160'.178'-185'.224'-234')) (128'-245')]-18-mer (GSTSGSGKPGSGEGSTKG) linker (246'-263') -L-KAPPA anti-ALB (264'-478') [V-KAPPA anti-ALB (Homo sapiens IGKV3-15*01 (85.7%) -IGKJ2*01 (90.9%) K123>Q (367'), CDR-IMGT [6.3.10] (290'-295'.313'-315'.352'-361')) (264'-371') -Homo sapiens IGKC*01, Km3 A45.1, V101, 15-KCv36 S126 (C-KAPPA A45.1 (417'), V101 (455'), C226>S (478') (372'-478')]], produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, non-glycosylated
VELAPRUMIG [USAN]
immunoglobulin scFvkh-L-VH-G1(CH1-h)_scFvkh-L-kappa, anti-[Homo sapiens CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], monoclonal antibody, bispecific, trivalent
velaprumig [INN]
Technical Codes
APB-A1
